{"data":[{"accessionNo":"0001231919-26-001150","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001974640","issuerName":"APOGEE THERAPEUTICS, INC.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-09-03","reportingPerson":"VHCP Co-Investment Holdings III, LLC","reportingCik":"0001750761","personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-09-08","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001231919-26-001150","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001974640","issuerName":"APOGEE THERAPEUTICS, INC.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-09-03","reportingPerson":"Venrock Healthcare Capital Partners III, L.P.","reportingCik":"0001738048","personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-09-08","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001231919-26-001150","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001974640","issuerName":"APOGEE THERAPEUTICS, INC.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-09-03","reportingPerson":"Venrock Healthcare Capital Partners EG, L.P.","reportingCik":"0001808512","personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-09-08","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001231919-26-001150","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001974640","issuerName":"APOGEE THERAPEUTICS, INC.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-09-03","reportingPerson":"VHCP Management III, LLC","reportingCik":"0001738053","personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-09-08","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001231919-26-001150","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001974640","issuerName":"APOGEE THERAPEUTICS, INC.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-09-03","reportingPerson":"VHCP Management EG, LLC","reportingCik":"0001808518","personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-09-08","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001231919-26-001150","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001974640","issuerName":"APOGEE THERAPEUTICS, INC.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-09-03","reportingPerson":"Bong Y. Koh","reportingCik":"0001615979","personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-09-08","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001231919-26-001150","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001974640","issuerName":"APOGEE THERAPEUTICS, INC.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-09-03","reportingPerson":"Nimish Shah","reportingCik":"0001698082","personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-09-08","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-26-105122","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock, $0.00001 par value","eventDate":"2026-09-03","reportingPerson":"Fairmount Healthcare Fund II L.P.","reportingCik":"0001769651","personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-09-03","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-26-105122","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock, $0.00001 par value","eventDate":"2026-09-03","reportingPerson":"Fairmount Funds Management LLC","reportingCik":"0001802528","personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-09-03","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-26-105122","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock, $0.00001 par value","eventDate":"2026-09-03","reportingPerson":"Peter Evan Harwin","reportingCik":"0001663607","personType":"IN,HC","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-09-03","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-26-105122","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock, $0.00001 par value","eventDate":"2026-09-03","reportingPerson":"Tomas Kiselak","reportingCik":"0001830177","personType":"IN,HC","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-09-03","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0000315066-26-001471","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001974640","issuerName":"APOGEE THERAPEUTICS INC","ticker":"APGE","cusip":"03770N101","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":2493136.73,"percentOfClass":4,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0000315066-26-001471","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001974640","issuerName":"APOGEE THERAPEUTICS INC","ticker":"APGE","cusip":"03770N101","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":2493136.73,"percentOfClass":4,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001897612-26-000527","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001974640","issuerName":"APOGEE THERAPEUTICS INC","ticker":"APGE","cusip":"03770N101","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"T. Rowe Price Investment Management, Inc.","reportingCik":null,"personType":"IA","sharesOwned":772969,"percentOfClass":1.3,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0000902219-26-000212","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Wellington Investment Advisors Holdings LLP","reportingCik":null,"personType":"HC","sharesOwned":564326,"percentOfClass":0.9,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0000902219-26-000212","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Wellington Group Holdings LLP","reportingCik":null,"personType":"HC","sharesOwned":564326,"percentOfClass":0.9,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0000902219-26-000212","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Wellington Management Group LLP","reportingCik":null,"personType":"HC","sharesOwned":564326,"percentOfClass":0.9,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-26-076853","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock, $0.00001 par value","eventDate":"2026-06-18","reportingPerson":"Tomas Kiselak","reportingCik":"0001830177","personType":"IN,HC","sharesOwned":6808789,"percentOfClass":9.99,"filedAt":"2026-06-23","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-26-076853","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock, $0.00001 par value","eventDate":"2026-06-18","reportingPerson":"Peter Evan Harwin","reportingCik":"0001663607","personType":"IN,HC","sharesOwned":6808789,"percentOfClass":9.99,"filedAt":"2026-06-23","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-26-076853","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock, $0.00001 par value","eventDate":"2026-06-18","reportingPerson":"Fairmount Healthcare Fund II L.P.","reportingCik":"0001769651","personType":"PN","sharesOwned":6713519,"percentOfClass":9.84,"filedAt":"2026-06-23","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-26-076853","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock, $0.00001 par value","eventDate":"2026-06-18","reportingPerson":"Fairmount Funds Management LLC","reportingCik":"0001802528","personType":"IA","sharesOwned":6713519,"percentOfClass":9.84,"filedAt":"2026-06-23","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001897612-26-000344","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001974640","issuerName":"APOGEE THERAPEUTICS INC","ticker":"APGE","cusip":"03770N101","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"T. Rowe Price Investment Management, Inc.","reportingCik":null,"personType":"IA","sharesOwned":10291220,"percentOfClass":16.8,"filedAt":"2026-04-08","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-26-036265","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock, $0.00001 par value","eventDate":"2026-03-26","reportingPerson":"Peter Evan Harwin","reportingCik":"0001663607","personType":"IN,HC","sharesOwned":6764974,"percentOfClass":9.99,"filedAt":"2026-03-27","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-26-036265","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock, $0.00001 par value","eventDate":"2026-03-26","reportingPerson":"Tomas Kiselak","reportingCik":"0001830177","personType":"IN,HC","sharesOwned":6764974,"percentOfClass":9.99,"filedAt":"2026-03-27","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-26-036265","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock, $0.00001 par value","eventDate":"2026-03-26","reportingPerson":"Fairmount Funds Management LLC","reportingCik":"0001802528","personType":"IA","sharesOwned":6666332,"percentOfClass":9.84,"filedAt":"2026-03-27","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-26-036265","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock, $0.00001 par value","eventDate":"2026-03-26","reportingPerson":"Fairmount Healthcare Fund II L.P.","reportingCik":"0001769651","personType":"PN","sharesOwned":6666332,"percentOfClass":9.84,"filedAt":"2026-03-27","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0000102909-26-000604","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics Inc","ticker":"APGE","cusip":"03770N101","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-26","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001897612-26-000311","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001974640","issuerName":"APOGEE THERAPEUTICS INC","ticker":"APGE","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2026-02-28","reportingPerson":"T. Rowe Price Investment Management, Inc.","reportingCik":null,"personType":"IA","sharesOwned":6213827,"percentOfClass":11.3,"filedAt":"2026-03-06","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001493215-26-000028","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001974640","issuerName":"APOGEE THERAPEUTICS, INC.","ticker":"APGE","cusip":null,"securityClass":"Common Stock, $0.00001 par value","eventDate":"2025-12-31","reportingPerson":"RTW Investments, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":2712097,"percentOfClass":4.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001493215-26-000028","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001974640","issuerName":"APOGEE THERAPEUTICS, INC.","ticker":"APGE","cusip":null,"securityClass":"Common Stock, $0.00001 par value","eventDate":"2025-12-31","reportingPerson":"Roderick Wong","reportingCik":null,"personType":"HC,IN","sharesOwned":2712097,"percentOfClass":4.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0000902219-26-000095","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Wellington Management Group LLP","reportingCik":null,"personType":"HC","sharesOwned":4746585,"percentOfClass":8.7,"filedAt":"2026-02-10","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0000902219-26-000095","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Wellington Group Holdings LLP","reportingCik":null,"personType":"HC","sharesOwned":4746585,"percentOfClass":8.7,"filedAt":"2026-02-10","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0000902219-26-000095","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Wellington Investment Advisors Holdings LLP","reportingCik":null,"personType":"HC","sharesOwned":4746585,"percentOfClass":8.7,"filedAt":"2026-02-10","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0000902219-26-000095","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Wellington Management Company LLP","reportingCik":null,"personType":"IA","sharesOwned":4746585,"percentOfClass":8.3,"filedAt":"2026-02-10","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0000102909-26-000084","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics Inc","ticker":"APGE","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":2857824,"percentOfClass":5.21,"filedAt":"2026-01-30","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-26-005916","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":null,"securityClass":"Common Stock, $0.00001 par value","eventDate":"2026-01-22","reportingPerson":"Peter Evan Harwin","reportingCik":"0001663607","personType":"IN,HC","sharesOwned":6047027,"percentOfClass":9.99,"filedAt":"2026-01-22","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-26-005916","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":null,"securityClass":"Common Stock, $0.00001 par value","eventDate":"2026-01-22","reportingPerson":"Tomas Kiselak","reportingCik":"0001830177","personType":"IN,HC","sharesOwned":6047027,"percentOfClass":9.99,"filedAt":"2026-01-22","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-26-005916","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":null,"securityClass":"Common Stock, $0.00001 par value","eventDate":"2026-01-22","reportingPerson":"Fairmount Funds Management LLC","reportingCik":"0001802528","personType":"IA","sharesOwned":5948385,"percentOfClass":9.82,"filedAt":"2026-01-22","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-26-005916","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":null,"securityClass":"Common Stock, $0.00001 par value","eventDate":"2026-01-22","reportingPerson":"Fairmount Healthcare Fund II L.P.","reportingCik":"0001769651","personType":"PN","sharesOwned":5948385,"percentOfClass":9.82,"filedAt":"2026-01-22","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0000938206-25-000048","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"DRIEHAUS CAPITAL MANAGEMENT LLC","reportingCik":null,"personType":"IA","sharesOwned":2158502,"percentOfClass":4.68,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-25-099401","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":null,"securityClass":"Common Stock, $0.00001 par value","eventDate":"2025-10-10","reportingPerson":"Peter Evan Harwin","reportingCik":"0001663607","personType":"IN","sharesOwned":5776881,"percentOfClass":9.99,"filedAt":"2025-10-14","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-25-099401","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":null,"securityClass":"Common Stock, $0.00001 par value","eventDate":"2025-10-10","reportingPerson":"Tomas Kiselak","reportingCik":"0001830177","personType":"IN","sharesOwned":5776881,"percentOfClass":9.99,"filedAt":"2025-10-14","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-25-099401","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":null,"securityClass":"Common Stock, $0.00001 par value","eventDate":"2025-10-10","reportingPerson":"Fairmount Funds Management LLC","reportingCik":"0001802528","personType":"IA","sharesOwned":5678239,"percentOfClass":9.81,"filedAt":"2025-10-14","canonicalUrl":"https://xoomar.com/markets/stocks/apge"},{"accessionNo":"0001104659-25-099401","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001974640","issuerName":"Apogee Therapeutics, Inc.","ticker":"APGE","cusip":null,"securityClass":"Common Stock, $0.00001 par value","eventDate":"2025-10-10","reportingPerson":"Fairmount Healthcare Fund II L.P.","reportingCik":"0001769651","personType":"PN","sharesOwned":5678239,"percentOfClass":9.81,"filedAt":"2025-10-14","canonicalUrl":"https://xoomar.com/markets/stocks/apge"}],"updatedAt":"2026-10-29T09:46:05.343Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/apge","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}